Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials

Cancer Treatment Reviews

Volumn 40, Issue 5, 2014, Pages 636-647

  Funakoshi, Tomohiro ^a   Latif, Asma ^b,c   Galsky, Matthew D ^b,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

Epidermal growth factor receptor; Fatal adverse events; Overall survival; Progression free survival; Severe adverse events; Small molecule tyrosine kinase inhibitor; Systematic review and meta analysis; Treatment discontinuation; Vascular endothelial growth factor receptor

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR; VASCULOTROPIN RECEPTOR;

ANEMIA; BLINDNESS; CANCER COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SKIN TOXICITY; SOLID TUMOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EPIDERMAL GROWTH FACTOR RECEPTOR; FATAL ADVERSE EVENTS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SEVERE ADVERSE EVENTS; SMALL-MOLECULE TYROSINE KINASE INHIBITOR; SYSTEMATIC REVIEW AND META-ANALYSIS; TREATMENT DISCONTINUATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

ADMINISTRATION, ORAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PATIENT SAFETY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84898408415     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2014.02.004     Document Type: Review

References (89)

1. Steeghs N., Nortier J.W., Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007, 14(2):942-953. [Epub 2006/11/15].
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353(2):123-132. [Epub 2005/07/15].
3. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356(2):115-124. [Epub 2007/01/12].
4. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. [Epub 2007/01/12].
5. Sternberg C.N., Davis I.D., Mardiak J., Szczylik C., Lee E., Wagstaff J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28(6):1061-1068. [Epub 2010/01/27].
6. National Cancer Institute: Common toxicity criteria version 3, <>. http://www.ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
7. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62(10):1006-1012. [Epub 2009/07/28].
8. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12. [Epub 1996/02/01].
9. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834. [Epub 1999/01/28].
10. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-560. [Epub 2003/09/06].
11. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101. [Epub 1994/12/01].
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. [Epub 1997/10/06].
13. Spano J.P., Chodkiewicz C., Maurel J., Wong R., Wasan H., Barone C., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008, 371(9630):2101-2108. [Epub 2008/06/03].
14. Kindler H.L., Ioka T., Richel D.J., Bennouna J., Letourneau R., Okusaka T., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12(3):256-262. [Epub 2011/02/11].
15. Rugo H.S., Stopeck A.T., Joy A.A., Chan S., Verma S., Lluch A., et al. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011, 29(18):2459-2465. [Epub 2011/05/11].
16. McDermott D.F., Sosman J.A., Gonzalez R., Hodi F.S., Linette G.P., Richards J., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group. J Clin Oncol 2008, 26(13):2178-2185. [Epub 2008/05/01].
17. Hauschild A., Agarwala S.S., Trefzer U., Hogg D., Robert C., Hersey P., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27(17):2823-2830. [Epub 2009/04/08].
18. Scagliotti G., Novello S., von Pawel J., Reck M., Pereira J.R., Thomas M., et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010, 28(11):1835-1842. [Epub 2010/03/10].
19. Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010, 304(19):2154-2160. [Epub 2010/11/18].
20. Molina J.R., Dy G.K., Foster N.R., et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol 2011, 29. (suppl; abstr 7513).
21. Baselga J., Segalla J.G., Roche H., Del Giglio A., Pinczowski H., Ciruelos E.M., et al. Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2012, 30(13):1484-1491. [Epub 2012/03/14].
22. Paz-Ares L.G., Biesma B., Heigener D., von Pawel J., Eisen T., Bennouna J., et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012, 30(25):3084-3092. [Epub 2012/08/02].
23. Goncalves A., Gilabert M., Francois E., Dahan L., Perrier H., Lamy R., et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012, 23(11):2799-2805. [Epub 2012/07/10].
24. Flaherty K.T., Lee S.J., Zhao F., Schuchter L.M., Flaherty L., Kefford R., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol 2013, 31(3):373-379. [Epub 2012/12/19].
25. Schwartzberg L.S., Tauer K.W., Hermann R.C., Makari-Judson G., Isaacs C., Beck J.T., et al. Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab. Clin cancer Res 2013, 19(10):2745-2754. [Epub 2013/02/28].
26. Gradishar W.J., Kaklamani V., Sahoo T.P., Lokanatha D., Raina V., Bondarde S., et al. A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer. Eur J Cancer 2013, 49(2):312-322. [Epub 2012/09/08].
27. Crown J., Dieras V., Staroslawska E., et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol 2010, 28:18s. (suppl; abstr LBA1011).
28. Bergh J., Bondarenko I.M., Lichinitser M.R., Liljegren A., Greil R., Voytko N.L., et al. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol 2012, 30(9):921-929. [Epub 2012/02/15].
29. Yi J.H., Lee J., Park S.H., Park J.O., Yim D.S., Park Y.S., et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012, 106(9):1469-1474. [Epub 2012/03/31].
30. Heist R.S., Wang X.F., Hodgson L., et al. CALGB 30704: a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012, 30. (suppl; abstr 7513).
31. Carrato A., Swieboda-Sadlej A., Staszewska-Skurczynska M., Lim R., Roman L., Shparyk Y., et al. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. J Clin Oncol 2013, 31(10):1341-1347. [Epub 2013/01/30].
32. Heymach J.V., Johnson B.E., Prager D., Csada E., Roubec J., Pesek M., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007, 25(27):4270-4277. [Epub 2007/09/20].
33. Heymach J.V., Paz-Ares L., De Braud F., Sebastian M., Stewart D.J., Eberhardt W.E., et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(33):5407-5415. [Epub 2008/10/22].
34. Herbst R.S., Sun Y., Eberhardt W.E., Germonpre P., Saijo N., Zhou C., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010, 11(7):619-626. [Epub 2010/06/24].
35. Boer K., Lang I., Llombart-Cussac A., Andreasson I., Vivanco G.L., Sanders N., et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs 2012, 30(2):681-687. [Epub 2010/09/11].
36. de Boer R.H., Arrieta O., Yang C.H., Gottfried M., Chan V., Raats J., et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011, 29(8):1067-1074. [Epub 2011/02/02].
37. Choueiri T.K., Ross R.W., Jacobus S., Vaishampayan U., Yu E.Y., Quinn D.I., et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol 2012, 30(5):507-512. [Epub 2011/12/21].
38. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899. [Epub 2005/07/27].
39. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the tarceva lung cancer investigation trial. J Clin Oncol 2007, 25(12):1545-1552. [Epub 2007/04/20].
40. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol 2007, 25(15):1960-1966. [Epub 2007/04/25].
41. Mok T.S., Wu Y.L., Yu C.J., Zhou C., Chen Y.M., Zhang L., et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2009, 27(30):5080-5087. [Epub 2009/09/10].
42. Pawel J.V., Papai-Szekely Z., Vinolas N., et al. A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC. J Clin Oncol 2011, 29. (suppl; abstr 7526).
43. Stinchcombe T.E., Peterman A.H., Lee C.B., Moore D.T., Beaumont J.L., Bradford D.S., et al. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol 2011, 6(9):1569-1577. [Epub 2011/07/01].
44. Lee J., Park S.H., Chang H.M., Kim J.S., Choi H.J., Lee M.A., et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2012, 13(2):181-188. [Epub 2011/12/24].
45. Mok T., Wu Y.L., Thongprasert S., et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. J Clin Oncol 2012, 30. (suppl; abstr 7519^).
46. Michael M., Pavlakis N., Clingan P., De Boer R., Johnston M., Clarke S. A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer. Oncol Rep 2012, 28(3):763-767. [Epub 2012/06/20].
47. Giaccone G., Herbst R.S., Manegold C., Scagliotti G., Rosell R., Miller V., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004, 22(5):777-784. [Epub 2004/03/03].
48. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004, 22(5):785-794. [Epub 2004/03/03].
49. Guarneri V., Frassoldati A., Ficarra G., Puglisi F., Andreetta C., Michelotti A., et al. Phase II, randomized trial of preoperative epirubicin-paclitaxel±gefitinib with biomarker evaluation in operable breast cancer. Breast Cancer Res Treat 2008, 110(1):127-134. [Epub 2007/08/10].
50. Santoro A., Comandone A., Rimassa L., Granetti C., Lorusso V., Oliva C., et al. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. Ann Oncol 2008, 19(11):1888-1893. [Epub 2008/08/01].
51. Vieitez J.M., Valladares M., Pelaez I., de Sande Gonzalez L., Garcia-Foncillas J., Garcia-Lopez J.L., et al. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143). Invest New Drugs 2011, 29(5):1038-1044. [Epub 2010/03/06].
52. Bernsdorf M., Ingvar C., Jorgensen L., Tuxen M.K., Jakobsen E.H., Saetersdal A., et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat 2011, 126(2):463-470. [Epub 2011/01/15].
53. Argiris A., Ghebremichael M., Gilbert J., Lee J.W., Sachidanandam K., Kolesar J.M., et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013, 31(11):1405-1414. [Epub 2013/03/06].
54. Di Leo A., Gomez H.L., Aziz Z., Zvirbule Z., Bines J., Arbushites M.C., et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008, 26(34):5544-5552. [Epub 2008/10/29].
55. Cameron D., Casey M., Oliva C., Newstat B., Imwalle B., Geyer C.E. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010, 15(9):924-934. [Epub 2010/08/26].
56. Sterne J.A., Gavaghan D., Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53(11):1119-1129. [Epub 2000/12/07].
57. Schutz F.A., Je Y., Choueiri T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011, 80(2):291-300. [Epub 2011/02/23].
58. Funakoshi T., Latif A., Galsky M.D. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev 2013, 39(7):818-830. [Epub 2013/03/05].
59. Jia Y., Lacouture M.E., Su X., Wu S. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis. J Support Oncol 2009, 7(6):211-217. [Epub 2010/04/13].
60. Chu D., Lacouture M.E., Weiner E., Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourinary Cancer 2009, 7(1):11-19. [Epub 2009/02/14].
61. Zhang L., Zhou Q., Ma L., Wu Z., Wang Y. Meta-analysis of dermatological toxicities associated with sorafenib. Clin Exp Dermatol 2011, 36(4):344-350. [Epub 2011/04/22].
62. Rosen A.C., Wu S., Damse A., Sherman E., Lacouture M.E. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab 2012, 97(4):1125-1133. [Epub 2012/03/02].
63. Fischer A., Wu S., Ho A.L., Lacouture M.E. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs 2013, 31(3):787-797. [Epub 2013/01/25].
64. Zhu X., Stergiopoulos K., Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009, 48(1):9-17. [Epub 2008/08/30].
65. Qi W.X., He A.N., Shen Z., Yao Y. Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis. Br J Clin Pharmacol 2013, 76(3):348-357. [Epub 2013/04/27].
66. Qi W.X., Shen Z., Lin F., Sun Y.J., Min D.L., Tang L.N., et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013, 75(4):919-930. [Epub 2012/08/14].
67. Funakoshi T., Latif A., Galsky M.D. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis. J Hum Hypertens 2013, 27(10):601-611. [Epub 2013/05/03].
68. Santoni M., Conti A., Massari F., Arnaldi G., Iacovelli R., Rizzo M., et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 2014, [Epub 2014/01/15].
69. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10(10):967-974. [Epub 2009/09/22].
70. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28(13):2280-2285. [Epub 2010/03/31].
71. Barni S., Cabiddu M., Guarneri P., Lonati V., Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012, 17(5):715-724. [Epub 2012/04/26].
72. Tam B.Y., Wei K., Rudge J.S., Hoffman J., Holash J., Park S.K., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006, 12(7):793-800. [Epub 2006/06/27].
73. Schutz F.A., Je Y., Richards C.J., Choueiri T.K. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012, 30(8):871-877. [Epub 2012/02/09].
74. Sivendran S., Liu Z., Portas L.J., Yu M., Hahn N., Sonpavde G., et al. Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. Cancer Treat Rev 2012, 38(7):919-925. [Epub 2012/06/02].
75. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127. [Epub 2008/09/12].
76. Van Cutsem E., Kohne C.H., Lang I., Folprecht G., Nowacki M.P., Cascinu S., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011, 29(15):2011-2019. [Epub 2011/04/20].
77. Douillard J., Siena S., Cassidy J., et al. Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 2011, 29. (suppl; abstr 3510^).
78. Perez E.A., Romond E.H., Suman V.J., Jeong J.H., Davidson N.E., Geyer C.E., et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011, 29(25):3366-3373. [Epub 2011/07/20].
79. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697. [Epub 2010/08/24].
80. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366(2):109-119. [Epub 2011/12/14].
81. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350(23):2335-2342. [Epub 2004/06/04].
82. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550. [Epub 2006/12/15].
83. Van Cutsem E., Tabernero J., Lakomy R., Prenen H., Prausova J., Macarulla T., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012, 30(28):3499-3506. [Epub 2012/09/06].
84. Su Y., Yang W.B., Li S., Ye Z.J., Shi H.Z., Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PloS one 2012, 7(4):e35629. [Epub 2012/04/28].
85. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011, 305(5):487-494. [Epub 2011/02/03].
86. Li X., Shan B.E., Wang J., Xing L.P., Guo X.J., Zhang Y.H., et al. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials. PloS One 2013, 8(11):e81897. [Epub 2013/12/07].
87. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29(11):1046-1051. [Epub 2011/11/01].
88. Anastassiadis T., Deacon S.W., Devarajan K., Ma H., Peterson J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011, 29(11):1039-1045. [Epub 2011/11/01].
89. Seruga B., Sterling L., Wang L., Tannock I.F. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011, 29(2):174-185. [Epub 2010/12/08].